Safety of Remdesivir in Covid Patients with Acute or Chronic Kidney Disease
Objective: The aim was to assess the safety of Remdesivir in Patients with Acute and Chronic Kidney Disease
Methodology: Quasi-experimental study was conducted at the Pak Emirates Military Hospital Rawalpindi from March 2021 to April 2022. A sample was collected through a non-random sampling method, recruiting those who were diagnosed with pneumonia caused by the COVID-19 virus. A total of 56 patients with acute or chronic kidney disease were the participants of our study. The inclusion criterion was patient with positive COVID PCR 7-10 days prior to the commencement of the study. Patients admitted to the hospital nephrology ward with any stage of AKI were also considered for inclusion in the study. However, patients under the age of 18 and those who refused to participate were excluded.
Results: The serum creatinine value were 125.15 Â± 8.61 u/L and 126.44 Â± 5.72 micromoles/L before and after Remdesivir use respectively. The serum ALT changed from 34.55 Â± 2.69 u/L to 33.26 Â± 1.85 u/L while Serum AST changed from 54.69 Â± 4.04 u/L to 55.42 Â± 3.09 u/L in patients with renal diseases when treated with Remdesivir for COVID-19.
Conclusion: This study concluded that Remdesivir had no statistically significant effect on serum creatinine, AST and ALT. It also showed that these values showed and above normal pattern from baseline before and after the administration of Remdesivir when given in participants of the study undergoing COVID treatment with AKI or CKD.
Copyright (c) 2023 Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.